People

Amrita Banerjee

Amrita Banerjee

Post Doc (UCSB)
My work is focused on developing oral insulin pills or transdermal insulin delivery formulations to significantly improve the quality of lives of patients with diabetes that self-administer insulin using injections. In addition, my work involves determining the influence of shape of nanoparticles in oral delivery to rationally engineer next generation efficient nanoparticles for oral delivery of drugs.
UCSB
Tyler Brown

Tyler Brown

Graduate Student
Delivering chemotherapeutics, neuroprotective agents, and other drugs to the brain has proven to be a challenging feat, primarily due to the physical Read more about Tyler Brown
Wyss Institute
3 Blackfan Circle, 2nd Floor
Room 206-7A, Center for Life Science
Boston, MA
Kelly Ibsen

Kelly Ibsen

Graduate Student
My research is focused on the use of ionic liquids in medical applications. For transdermal drug delivery, ILs can enhance penetration of macromolecules like Read more about Kelly Ibsen
Wyss Institute
3 Blackfan Circle, 2nd Floor
206-8B, Center for Life Science
Boston, MA
Prof. Samir Mitragotri

Professor Samir Mitragotri

Principal Investigator
Hiller Professor of Bioengineering and Hansjorg Wyss Professor of Biologically Inspired Engineering
Core Faculty Member, Wyss Institute for Biologically Inspired Engineering
Prof. Mitragotri has made groundbreaking contributions to the field of biological barriers and drug delivery. His research has advanced fundamental understanding of biological barriers and has led to the development of new materials as well as technologies for diagnosis and treatment of various ailments including diabetes, cancer, cardiovascular diseases, skin conditions and infections, among others. Many of his technologies have advanced to human clinical studies and products. At the same time, fundamental understanding developed through his research has advanced the understanding of the biology of barriers in the human body.
211 Pierce Hall
Anusha Pusuluri

Anusha Pusuluri

Graduate Student
My graduate work focuses on engineering clever cancer-selective drug delivery platforms by combining our lab's unique understanding of drug combination fundamentals together with cutting edge bio-recognition agents. Our innovative strategy employs a carefully controlled drug combination, that is inherently cancer specific, for superior dose reduction and enhanced tumor recognition thereby enabling exceptional therapeutic effects.